All
FDA Approves Lynparza for BRCA-Positive Breast Cancer
January 12th 2018Lynparza (olaparib) was granted approval by the Food and Drug Administration (FDA) for the treatment of patients with BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. Also, patients who have HR-positive disease should have prior endocrine therapy or they would not be considered appropriate for such treatment.
Personalized Care Plans Must Consider Social Disparities
January 11th 2018Racial and socioeconomic status disparities can affect all types of lung cancer treatment – including surgery, chemotherapy and radiation. However, researchers may not be aware of this, since many of these groups are underrepresented in lung cancer clinical trials.
Drug Shows Promise in Reducing Oral Mucositis in Patients With Head and Neck Cancer
January 11th 2018Oral mucositis causes pain, the inability to eat which can also lead to nutritional problems, and an increased risk for infection as a result of open sores. In turn, these symptoms can lead to reduced quality of life, chemotherapy or radiation dose-limiting, and increased treatment costs from antibiotics or narcotics or additional or longer hospital stays.
Combinations May Be the Future of Immunotherapy in Ovarian Cancer
January 10th 2018To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can be combined with other agents to benefit patients.